(ECS)
The endocannabinoid system (ECS) is as good a place to start with when we discuss the confronting and impressive combination of anatomy, physiology and psyche which is the human form because ECS is considered the ‘universal regulator.’
This ‘dimmer switch’ fine tunes processes throughout our whole body.
ERRRR—what?
Consider a lock and key system where the receptors are the locks. These aren’t any locks though…they can change what keys fit them! (we will get to that later)
The Locks
The main locks in this system are the CB1 and CB2 receptors. These receptors are the proteins imbedded in your cells which ‘unlock’ when specific keys fit into them. The keys are fat based molecules which we will discuss now…
The Keys
Anandamide- (AEA) the ‘bliss molecule’ which deals in the reward system and mood.
2-Arachadonoylglycerol- (2AG) present in much higher concentrations and dealing in immunity and baseline stability.
The Regulators
FAAH- destroys anandamide
MAGL-destroys 2-AG
Review
| Component | Category | Primary Locations | Core Functions / Roles | Key Characteristics |
|---|---|---|---|---|
| CB1 | Cannabinoid Receptor | Central nervous system (brain, spinal cord); peripheral tissues | Modulates neurotransmitter release, pain perception, memory, and appetite | One of the most abundant G-protein coupled receptors in the brain. |
| CB2 | Cannabinoid Receptor | Immune system, microglia, spleen, tonsils; peripheral organs | Modulates immune response, inflammation, and tissue protection | Primarily peripheral; expression increases significantly during tissue injury or inflammation. |
| Anandamide (AEA) | Endocannabinoid (Ligand) | Synthesized on demand in neurons and peripheral tissues | Regulates mood, sleep, appetite, and pain memory | High affinity for CB1 but low efficacy; often called the “bliss molecule.” |
| 2-Arachidonoylglycerol (2-AG) | Endocannabinoid (Ligand) | High concentrations in the central nervous system | Acts as a full agonist to regulate neurotransmission and inflammation | Present at much higher levels in the brain than AEA; binds strongly to both CB1 and CB2. |
| FAAH (Fatty Acid Amide Hydrolase) | Metabolic Enzyme | Intracellular membranes, primarily in the brain and liver | Breaks down Anandamide (AEA) into arachidonic acid and ethanolamine | Primary regulator of AEA signaling; inhibiting FAAH raises AEA levels to reduce pain and anxiety. |
| MAGL (Monoacylglycerol Lipase) | Metabolic Enzyme | Presynaptic nerve terminals and various peripheral tissues | Breaks down 2-AG into arachidonic acid and glycerol | Responsible for degrading about 85% of 2-AG in the brain; key link to neuroinflammatory pathways. |
| Feature | 2-Arachidonoylglycerol (2-AG) | Anandamide (AEA) |
|---|---|---|
| Receptor Efficacy | Full Agonist (highly potent activator of CB1 & CB2) | Partial Agonist (weaker activator) |
| Brain Abundance | Very High (roughly 1,000x higher levels than AEA) | Low (highly localized) |
| Primary Target | Equal affinity for both CB1 and CB2 | Prefers CB1 and vanilloid (TRPV1) receptors |
| Degradation Enzyme | Broken down primarily by MAGL | Broken down primarily by FAAH |